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RENAL homograft recipients have been 
reported to have a high incidence of livu 
disease in the post-transplantation period.2f• 
29. 31. 56. 65, 70 It was assumed that the im-
munosuppressive agents were responsible, 
either by their hepatotoxicity or because the 
consequent weakening of the host immune 
system permitted the frequent development 
of virus hepatitis. An accurate distinction 
between these two general possibilities was 
not feasible until recently. Then, with the 
description of tests which permitted identi-
fication of the hepatitis associated or Aus-
tralia (Au) antigen, 7 , 9, 58 it became possible 
to deciSively study at least one variety of 
virus hepatitis in transplant recipients. 
In this communication, a series of ob-
servations related to the problem of hepatic 
damage with or without hepatitis in a large 
transplantation program will be presented. 
These observations will include: (1) The 
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10176-01, AI-AM-08898, AM-07772, GM-01686, 
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incidence of serologic evidence of Au anti-
genemia, (2) Comparison of immunodif-
fusion, immuno-osmoelectrophoresis, elec-
trO-immunodiffusion, and complement 
fixation tests for the detection of hepatitis 
in immunosuppressed patients, ( 3 ) Thn 
clinical course followed by immunosup-
pressed patients infected with the serum 
hepatitis virus, (4) Evaluation of the anti-
complementary activity (ACA) recently de-
scribed by Shulman and Barker64 and 
Purcell et al.60 as an indicator of complexes 
of Au antigen and antibody, and, (5) De-
scription of the serologic changes and clini-
cal course of a patient dying with chronic 
aggreSSive hepatitis, Au positive, who was 
treated with liver replacement. 
Methods 
Specimens were taken from 225 normal 
volunteers, from 83 recipients of renal 
homografts, from 10 liver recipients, and 
from one cardiac recipient. Immunosup-
pression for the transplant patients was with 
azathioprine and prednisone 65 to which 
horse antilymphocyte globulin (ALC) was 
added in about half the cases.70 
All the blood samples were allowed to 
clot for about one hour at room tempera-
ture. The sera were then separated by cold 
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centrifugation and stored at - 20 or -70° C. 
The analyses were subsequently performed 
independently in two laboratories. In one 
(hereafter called Laboratory 1) the screen-
ing was done with micro-Ouchterlony aga-
rose gel immunodiffusion (AG), 46 or elec-
troimmunodiffusion (EID )46 technics, re-
acting the patient's serum against standard 
sera known to contain Au antigen or anti-
Au antibody. The standard serum contain-
ing Au antigen was obtained from a patient 
treated with renal homotransplantation in 
February, 1968, who did not have obvious 
liver disease in spite of chronic Au anti-
genemia. The standard serum containing 
anti-Au antibody was taken from another 
renal recipient of approximately the same 
era who had developed chronic liver disease 
without perSistent Au antigenemia. 
In Laboratory 2, fewer recipients were 
studied, but analysis of the sera was more 
exhaustive. The Au antigen was detected 
with the micro-Ouchterlony (AG), 53 im-
munoelectro-osmophoresis (IEOP), 16, 59 and 
complement fixation (CF) 63, 64'" tests. In 
all three systems quantitation was obtained 
by serially diluting the patient's sera with 
gelatin-veronal buffer (GVB++); the amount 
of Au antigen was expressed as the reci-
procal of the greatest dilution in which a 
positive reaction was elicited by that test. 
The standard sera containing Au antigen 
were obtained from seven patients whose 
antigen appeared identical by the Ouch ter-
lony method. One of these serum donors 
was a renal transplant recipient, another 
had chronic lymphatic leukemia, two were 
hemophiliacs and the other three did not 
have an associated disease; four of the 
seven patients had received multiple blood 
transfusions at some previous time. The 
serum containing anti-Au antibody was 
donated by the same patient described in 
the preceding paragraph. However, the IgG 
was removed from the crude serum by am-
monium sulphate fractionation, followed by 
"One drop of guinea pig complement was used 
having a concentration of 1.5 CH 50 units/m!' 
TABLE 1. Incidence of Au Antigen by Random Single 
Sampling in Homograft Recipients from One Month 
).l"o. 
89 
to 8 Years after Operation, using I mmuno-
diffusion or Electro-immunodiffusion Tests 
(or Screening. Laboratory No. 1* 
Negative for 
Au Antigen Anti-Au Au Antigen 
Positive Antibody and Antibody 
15 (16.9%) 2 (2.2%) 72 (80.9%) 
* The incidence was actually higher than shown since 
several additional cases were detected in Laboratory 
No.2 within the negative group, by the more sensitive 
method of complement fixation. 
diethylaminoethyl (DEAE) cellulose chro-
matography. Almost all the antibody ac-
tivity was recovered. 
In all sera checked for Au antigen, anti-
Au antibody also was looked for with AG, 
lEOP, and CF by reversing the positions of 
the patient and standard sera and using the 
Au-containing serum from the renal trans-
plant recipient described earlier as the 
reference antigen. 
The anti-complement activity (ACA) in 
the sera was quantitated by a hemolysis 
method.43 To serial 2-fold dilutions of the 
patient sera was added an equal volume 
( one drop) of 1.5 CH50 units/ml of normal 
human complement. After incubation for 
60 minutes at 37° c., one drop of sensitized 
sheep erythrocyte suspension containing 
1 X 108 celIs/mI. was added. Hemolysis 
was graded after an additional 60 minutes 
incubation and centrifugation at 1,000 rpm 
for 5 minutes. 
An effort was made to distinguish ACA 
from the other well known heat-stable 
human complement inhibitor, C3 inacti-
vator.74 C3 inactivator was looked for with 
the immune adherence test using the EA 
4, 3 cell system. 74 In addition, rheumatoid 
factor ( RA) possesses anticomplementary 
activity. 30, 34 RA was detected with the 
latex fixation test." 
In addition, the sera of four renal patients 
who were known to possess both ACA and 
"Latex RA Kit, Hyland Corporation, Los 
Angeles, California. 
Ann. Surg .. Oct. 1971 
Vol. 174· No.4 
HEPATIC DISEASE IN HOMOGRAFT RECIPIENTS 622 
TABLE 2. Comparison of A ustralia Antigen Detection 
witiz AG, EID, IEOP, and CF in 50 Cases Studied 
Re petitively after Transplantation 
:1\0. Positive 
AG EID IEOP CF 
15 15 15 23* 
* These 23 included 8 detected only by CF plus the 
15 diagnosed with all the other methods. 
C3 inactivator were submitted to DEAE-
cellulose"" column chromatography57 after 
special cellulose washing.75 In addition, 
further purification of ACA elutions from 
the DEAE column was obtained by gel 
filtration with Sephadex G-200 and the re-
fined product was re-examined serologically 
for ACA activity. 
The decomplemented (heated at 56° C. 
for 30 minutes) sera from four other pa-
ticnts who possessed high titer ACA were 
examined by electronmicroscopy. To two 
of the sera of renal recipients which had An 
antigen detectable by all the methods used, 
purified anti-Au IgG was added; the re-
sulting precipitate was examined ultra-
structurally. In addition, the ACA in the 
sera of two liver recipients was examined 
ultrastructurally after being purified by 
ammoniulll sulphate precipitation, DEAE 
chromatography, Sephadex G-200 gel filtra-
tion, pol)'"inyl chloride (Pevikon) block 
electrophoresis'" and recycling through 
Sephadex G-200. One of these hepatic pa-
tients had an ACA titer ranging as high as 
1/1,024 but no serologic evidence of Au 
antigcnemia. The other had an ACA titer of 
1:48; An antigen became detectable by CF 
only (Table 6). 
Results 
Incidence of Au Antigen or Anti-Au 
Antibody 
In Laboratory 1 the sera from 83 renal, 
five hepatic, and one cardiac transplant re-
""Lot ]\'0. 2·107, Brown Company, Berlin, New 
Hampshire. 
"Pevikoll C870, Fosfatbolaect, Stockholm (5), 
Sweden. 
cipients were studied with electroimmuno-
diffusion (EID) and/or with AG (Table 1). 
The results were negative for Au antigen 
and Anti-Au antibody in 72 cases (80.9%). 
Fifteen (16.970) of the patients had Au 
antigenemia including one of the five liver 
and 14 of the 83 kidney recipients. The final 
two (2.270) did not have detectable 
Australia antigen but there was unequivocal 
evidence of anti-Au antibody. 
The foregoing statistics were collected by 
studying single serum samples obtained 
from the individual patients from one 
month to 8 years after transplantation, at 
re-hospitalization or at routine clinic visits. 
It was conceivable in some cases in which 
the results were negative that evidence of 
serum hepatitis had been present with these 
tests earlier, but with the resolution of the 
positive serologic findings. To evaluate this 
possibility, serial stored sera were examined 
both in Laboratories 1 and 2 from 3.5 of the 
72 patients pronounced to be Au negative 
on the basis of their single samples, includ-
ing the two recipients who had anti-Au 
antibody. In these 35 recipients (of 33 kid-
neys, one liver, and one heart), three to 31 
serial samples were examined over collec-
tion intervals that ranged from 2 to 35 
months, with an average of 14.4 ± 9.1 
(S.D.) months. None of the 35 patients had 
the Au antigen in any of their specimens as 
detected with the AG, EID, and lEap ex-
aminations. Thus the single sample analysis 
with the precipitating technics appeared to 
provide adequate gross screening for post-
transplantation epidemiologiC studies since 
no patient who exhibited the Au anti-
genemia with those tests ever had disap-
pearance of the positive serologic findings. 
However, it will be pointed out in the next 
section that the incidence derived with the 
precipitating tests was an under estimation 
since several additional cases were detected 
by the more sensitive method of comple-
ment fixation. 
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AG -- ---- - + + + 
IEOP -- ---- - ---- 1/32 1/64 1/256 FIG. 1. The course of 
a patient who received 
two kidney homografts 
almost a year apart. 
Hepatitis was never di-
agnosed on clinical 
grounds or by biochemi-
cal c r i teria; the de-
pressed serum pro t e in 
concentration prior to 
the second transplanta-
tion was due to homo-
graft nephrosis and pro-
teinuria. Yet, the com-
plement fixation was 
positive at all times, even 
preceding the first trans-
plantation. After the sec-
ond transplantation at 
which time immunosup-
pression was intensified, 
all Au tests became posi-
tive. See text for expla-
nation of abbreviations. 
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Comparative Sensitivity of Detection 
Methods 
In the 15 recipients in the preceding 
section who were known to be Au positive 
and in one heart, one liver, and 33 renal 
recipients who were thought to be Au nega-
tive, serial serum samples collected over 
periods of one to 54 months were studied 
by all four of the methods shown in Table 
2. An average of 13.4 ± 11.1 (S.D.) speci-
mens were examined from each patient. 
The 15 recipients who were found to have 
the Au antigen with the precipitating tests 
(AG, EID, and IEOP) were also positive 
with complement fixation (CF) as defined 
by a titer of 1:4 or higher. In addition, 8 
patients of the 35 who were negative for 
Au antigen by the precipitating tests had 
Significant increases in CF at some time 
indicating that Au antigen had been present 
even though this had been missed by AG, 
EID, or IEOP. 
In addition to proViding a higher yield, 
the CF was invariably the most sensitive 
way to follow individual patients. It be-
came positive earlier and evolved more 
dramatically than any other test (Fig. 1). 
The 225 people who were thought to be 
12 12 6 12 12 4 5 6 7 8 9 10 II 12 
TIME IN MONTHS 
normal were examined with AG, IEOP, and 
CF. None had positive tests. 
Clinical Manifestations of Au Antige-
nemia 
Forty-five of the non-hepatic transplant 
recipients (44 renal and one cardiac) who 
were studied serologically at frequent post-
operative intervals also had concomitant 
liver function tests. Consequently, it was 
possible in these 45 cases to correlate ab-
normalities in hepatic function with the 
presence or absence of Au antigenemia. 
Au Positive by All Tests. Three of the 
12 kidney recipients who were repeatedly 
studied (Fig. 2) had definite Au anti-
genemia prior to transplantation detected 
by the precipitating methods (AG and 
lEOP) as well as by CF. Two other pa-
tients were positive preoperatively with CF 
only; 16 and 50 months postoperatively the 
AG and IEOP in these two patients became 
positive. The details of one of the latter 
cases is shown in Figure 1. In this patient, 
the CF test was elevated in variable titers 
on every occasion for more than 4 years be-
fore the diagnosis of Au antigenemia could 
be confirmed by AG and IEOP. The seven 
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FIG. 2. The serologic findings and liver func-
tion tests in one cardiac and 18 renal recipients 
who were diagnosed as having Au antigenemia. In 
the 7 cases shown above, only the complement 
fixation test became positive. An antigen was de-
tectable by all the diagnostic methods in the bot-
tom 12 cases. When an arrow is at the extreme 
left of an individual patient's schematic summary, 
the first studies were obtained sometime after the 
transplantation. Otherwise, the symbols to the left 
of the arrows represent preoperative determina-
tions. In Cases LD 40 and LD 50, the first ex-
aminations were more than 5 years after a first 
transplantation, but before a second transplanta-
tion. LD 108 was studied both before and after 
each of his 2 transplantations which were almost 
4 years apart; details of this case are also sum-
marized in Figure 1. 
patients who had no evidence of the Au 
antigen before transplantation or at the time 
of the first examination postoperatively 
developed positive serologic tests from one 
to 35 (average 1O~F months later (Fig. 2). 
Once the full battery of analyses showed 
the Au antigen, these findings did not 
permanently disappear in any instance in 
the subsequent followup intervals of 4 to 30 
(average 13.7) months (Fig. 2). The liver 
function tests of the 12 patients obtained 
at the same time as the various serologic 
examinations are summarized in Figure 2. 
There was only one isolated example (Case 
LD 40) of serious acute hepatic malfunc-
tions, defined as two SCOT tests exceeding 
250 I. U . ( normal < 50) or bilirubin of 
greater than 2 mg./100 m!. Minor function 
abnormalities were observed at some time 
in six other cases, almost invariably con-
sisting of relatively trivial inereases in 
SCOT (50 to 250 I. U. ). The latter trans-
aminase abnormalities are still present in 
five of the 12 recipients. On the other hand, 
five of the patients who have had serologic 
evidence of hepatitis for one to more than 
4 years had no evidence whatsoever of 
hepatic dysfunction at any time. 
Au Positive by C.F. Only. One patient 
had an elevated CF titer before operation 
and another one was positive when first 
tested 3% years post-transplantation. The 
other five recipients developed positive CF 
examinations from 1 to 13 months (average 
4.2) after operation. In contrast to the 
precipitating tests, a positive CF result did 
not neccssarily imply chronicity of Au anti-
genemia since reversion to normal occurred 
in four of the seven patients (Fig. 2). 
Abnormal liver function tests of a minor 
nature were seen transiently in two of the 
seven patients (Fig. 2). A third recipient 
(LD 224) became deeply jaundiced at the 
same time as there was evidence of hepatic 
necrosis and very low grade increases in the 
CF ti tel'S (Fig. 3). Except for this case, 
there was no correlation between abnormal 
CF tests and hepatic dysfunction. 
Au Negative by All Tests. Of the 24 
patients who never had Au antigen despite 
frequent testing (Fig. 4), 14 (58.3%) had 
BILIRUBIN 
[mIiIiOOml) 
AG 
IEOP 
CF 
TITER 
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TITER 
SGOT (IU) 
TOTAL PROTEIN-to 
Ai~~~~~~-I~-IK_K_ : 1 _______ - ~---------- -- ------
; -1-·------------___ .. --- "". __ _ 
ItE!"!. I f 1I 4 ~ • 1 • • IG " 
T/tAHSPLA/liTAnON TIME IN MONTHS 
FIG. 3. The course of a patient (LD 224) who 
developed evidence of severe hepatitis after trans-
plantation. At the same time, he had low grade 
increases in complement fixation titers of Au anti-
gen as well as slightly anticomplementary activity 
in the serum. Note the transient secondary com-
plement fixation titer rise more than a year later. 
625 TORISU AND OTHERS Ann. pur~ .. Oct. 1971 
\'01. 174· No.4 
L D 263-ttl * 
L D 267-
L 0 262 ±tI* 
L 0 178 - ---
L 0269 i---
L D 268- - - (-x-) 
L D 264 ----
CD 52 - ~--
C D41 - - -
C D44 - ---1 
L D248 - -
L D246- ::J Cl ffi-
L D 209-
- Cl Cl 
L D212 - --- -
LDI75--- -
L D240 - - -
t 
-
0 
0 
* 
-
-
-
tI::J 
t-) 
--
TRANSPLANTATION 
NEGATIVE ALL Au TESTS 
MINOR LIVER FUNCTION CHANGE 
SEVERE LIVER FUNCTION CHANG 
liVER DISEASE CAUSED OR 
CONTRIBUTED TO DEATH 
-
-
S 
ES 
C D34 
-:±J Cll::Jt) 
C D33 
- - - - - -
L D 199 - ±I::I - - -
C 029 - --1 - (-1 -
L D214 -- -- -
L D 176 ::I - - - -
- 1 H -
LD2 - - -
-
CD 17 -J:] R FEI 1-1-1-1 1-1 1:1:1* 
o 4 8 12 16 20 24 28 32 36 
TIME IN MONTHS 
FIC;. 4. The negative serologic findings (AG, 
IEUP, and CF) and contemporaneous liver fllnc-
tioll tests in 24 patients who did not have AlI 
ar,tigcnelllia. The explanation for the arrows is 
the same as in the caption for Figure 2. Note that 
liver disease caused or contributed to three deaths. 
evidence of hepatic dysfunction at some 
time after transplantation. The incidence of 
functional abnormalities was thus actually 
slightly higher than in the recipients shown 
AG 
IEOP 
CF 
ACA 
TITER 
SGOT 
(I.U) 
in Figure 2 whose sera had evidence of the 
Au antigen but who had hepatic dysfunc-
tion at a rate of only 10 in 19 (52.6%). 
The liver disease in the Au negative pa-
tients was usually trivial. However, there 
were five patients who had serious hepatic 
malfunction as defined earlier in terms of 
SCOT and bilirubin rises. Liver disease 
either caused or contributed importantly to 
the deaths of three of these five recipients 
(Fig. 4, 5). 
In one of the five patients with serious 
liver disease, azathioprine toxicity was so 
strongly considered that this drug was 
stopped and replaced with cyclophospha-
mide (Fig. 6). A marked improvement in 
hepatic function was noted in the ensuing 
7 weeks. These observations were not 
thought either to weaken or strengthen the 
hypothesis of azathioprine hepatotoxicity in 
this patient. 
Anti-Au Antibody. In all the patients 
who had Au antigen by any test, anti-
Au antibody was looked for with AG, lEOP, 
and CF, but it was never detected. In addi-
tion, all the patients with negative Au tests 
were examined. Two of these latter reci· 
pients had unequivocal evidence of anti-Au 
antibody (Table 3) which devcloped one 
week and one year respectively after trans-
plantation, without ever having detectable 
FIG. 5. The course of 
a recipient (CD 17) of 
4 snccessive renal homo-
grafts who despite COIl-
sistently negative serol-
ogy for An antigen 
showed significant aber-
rations of liver function 
tests over a 3-year pe-
riod. Following the 
fourth transplantation, 
she became deeply jaun-
diced and died 3 weeks 
later. 
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.,.FIRST TRANSPLANT ...-SECON!) TRANSPLANT 
Au antigenemia. The first of these patients 
has had no hepatic functional abnormalities. 
The second one has had very severe liver 
disease which has become chronic. A biopsy 
FIG. 6. A renal recipi-
ent (LD 246) whose he-
patic functional derange-
ments following a sec-
ond transplant were sus-
pected to be caused by 
az a th ioprine toxicity. 
Cyclophosphamide ( Cy-
toxan®) was substitutcd 
for azathioprine. The se-
rum bilirubin receded 
over the next 7 weeks, 
and subsequently it has 
returned nearly to nomal. 
in August, 1970 was read as chronic ag-
gressive hepatitis with early cirrhosis. 
In both cases, anti-complementary ac-
tivity (ACA) has been present in low titers 
TABLE 3. TI,'" Patients W 110 Developed A nti-A 1l A ntibody wit/lOut Ever Manifesting Au Antigenemia 
-----
Au Antigen Anti-Au Antibody Hepatic Function 
Bili-
rubin Albumin 
Date AG lEOP cr** ACA** AG IEOP** CF** SGOT (mg./ (Gm./ 
Titer Titer Titer Titer (LD.) 100 ml.) 100 mI.) 
Case I 
2-19-68* <2 8 <2 <2 27 0.6 3.2 
3-12-68 <2 8 <2 <2 60 0.5 2.8 
5-23-68 <2 8 <2 <2 120 0.3 3. t 
3-6-69 <2 4 <2 2 86 2.0 2.8 
6-24-70 <2 4 <2 4 55 1.7 2.7 
7-5-70 <2 4 <2 4 90 2.1 2.7 
7-16-70 <2 8 + 2 16 70 2.0 3.1 
8-14-70 <2 8 + 16 128 40 6.3 3.0 
9-/-70 <2 8 + 16 128 42 2.8 2.7 
9-12-70 <2 8 + 16 128 44 1.4 2.6 
9-29-70 <2 8 + 16 128 60 1.0 2.7 
12-8-70 <2 8 + 8 32 68 1.1 3.1 
Case 2 
8-21-70' <2 4 <2 7 0.7 3.0 
~ef-TM <2 4 + 8 32 
9-7-70 <2 8 + 4 8 
9-21-70 <2 8 + 2 8 27 0.7 3.2 
9-25-70 <2 1\ + 2 8 
10-23-70 <2 8 1 4 
11-2-70 <2 4 1 4 50 0./ 3.9 
11-27-70 <2 4 + 4 8 
12-7-70 <2 4 + 2 8 38 0.3 3.5 
* These were pre-transplantation studies. The operations were on February 19, 1968 (Case 1) and August 27, 
1970 (Case 2). 
** The titers are expressed as the reciprocal of the greatest dilution giving a positive reaction. 
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TABLE 4. Relation of Anticomplementary Activity (ACA) 
and Latex Fixation Tests for A ustralia (A 11) Antigen 
in 48 Renal and One Cardiac Transplant 
Recipients 
--- --------
--_. 
No. with ACA 
titer :: 1: 16 
No. with Positive 
Latex Fixation 
Test 
Au+ by all 
Tests 
14/14 
5/14 
A.u+ by CF 
only 
6.7 
1/7 
Au-
1/28* 
2/21; 
* Includes the two patients who had anti-Au anti-
body; neither had significant ACA. 
during most of the period of study. The 
interpretation of this finding will be con-
sidercd later on. 
Anticomplementary Activity 
Renal and Cardiac Recipients. One car-
diac and 48 renal recipients who had re-
peatcd examinations for Au antigen also 
had ACA dctermination at these times. In 
each of the patients who was Au positive 
by all the detection methods, ACA was 
increased to or above a titer of 1: 16 (Table 
4). The same was true for six of the seven 
patients who had the Au antigen detectable 
onlv bv CF. In contrast, onlv one of 28 pa-
tie~ts ill whom tbcre was no 'evidence of the 
Au antigen had an ACA titer as high as 
1: 16 (Table 1) . 
In the patients with Au antigen, the sig-
nificant ACA titers usually developed at or 
about the same time as one or more of the 
Au test became positive, as exemplified in 
Figure 1. However, this temporal associa-
tion was sometimes not precise, with the 
ACA rising either before or after the other 
serologic changes. While there was a good 
general correlation between ACA and Au 
antigenemia, there was no clear association 
with the rheumatoid factor as detected by 
the Latex fixation test (Table 4). 
Hepatic Recipients. Of the hepatic re-
cipients, there were eight whose ACA was 
determined serially before and after opera-
tion. All eight had significant increases of 
ACA titer. The elevations occurred both in 
patients with and in those without Au anti-
genemia. In fact, the highest ACA titer 
( 1: 1,024) was in a child who never had any 
other serologic evidence of the Au antigen 
(Patient 5, Table 5). Similarly, the rheu-
matoid factor could not be correlated with 
Au antigenemia. 
Normal People. There were 225 normal 
controls of whom none had any serologiC 
evidence of Au antigen (see earlier). Of 
this group, 208 had no ACA and the other 
17 had titers of 1: 2 to 1: 8, too low to be 
considered significant. 
The Nature of ACA. The evidence in 
the preceding sections (Tables 4 and 5) 
showed that ACA was not rheumatoid 
factor. In addition, the titers of C3 inac-
tivator were determined in seven of the 
eight liver recipients shown in Table 5 and 
in 30 renal recipients (15 Au positive, 15 
Au negative). These fluctuated remittently, 
but not in relationship to ACA. A difference 
between ACA and C3 inactivator was 
proveu by the DEAE cellulose chromato-
graphy and Sephadex G-200 gel filtration 
which pcrmitted separation of the two sub-
stances. With both chromatographic tech-
nics, the ACA and C3 in activator werc at 
widely separated peaks (Figure 7). 
The electron micrographic studies with 
the precipitates or purified ACA from the 
sera of four recipients (two renal and two 
hepatic) who possessed high ACA titers 
are summarized in Table 6. An example of 
what was construed as a complex of virus 
and antibody is shown in Figure 8. The only 
TABLE 5. Relation of ACA to the La/ex Fixation Gild 
Au Antigen Tests in Eight Liver Recipients 
Highest Latex 
Patient ACA Titer Au 'rests Fixation 
1 1:256 All+ 
2 1:128 All + + 
3 1:32 CF+ 
4 1:96 CF+ + 
5 1: 1024 + 
6 1:32 
7 1:32 
8 1:32 + 
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FRACTIONATION 2: SEPHADEX G-200 FIG. 7. Elutions of 
ACA and C3 in activator 
from the serum of Ii 
liver recipient known to 
have a high ACA titer, 
but Au negative by all 
tests. The first fractiona-
tion was with a DEAE-
cellulose column, using 
phosphate buffer, the 
ionic strength of which 
was adjusted with so-
dium chloride. The incli-
vidual tubes were ana-
lyzed for protein content 
(expressed as o{ltical 
density), and titered for 
C3 inactivator and ACA . 
Tubes 176-210, contain-
ing the ACA, were then 
pooled and submitted to 
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ation (Inset). \Vith the Sephadex step, the ACA was present in a narrow band of the eluate, but C3 
inactivator could not be detected in any of the samples. 
specimen that did not contain easily identi-
fiable virus-like particles came from the 
purified ACA of the liver recipient who was 
serologically Au negative. 
Liver Replacement for Chronic Aggres-
sive Hepatitis, Au Positive 
A 27-year-old woman with end-stage 
hepatic disease and remittent encephalo-
pathy was treated on August 9, 1970 by 
total removal of a 688 Gm. cirrhotic liver 
and replacement with a cadaveric homo-
graft. Between 1959 and 1964 she had been 
an intravenous drug user and was admitted 
to a Los Angeles Hospital in 1964 with a 
bout of acute hepatitis from which she was 
thought to have promptly recovered. How-
ever, in July, 1969, she was seen by Dr. 
Allen Rediker of the University of Southern 
California, Los Angeles, who diagnosed 
chronic aggressive hepatitis after liver 
biopsy. Moreover, from then until the time 
of transplantation almost a year later, six 
blood samples were Au positive by the AG 
test performed in California. Using stored 
sera, these findings were the same in the 
Colorado Laboratories 1 and 2. In addition, 
there was confirmatory evidence of per-
sistent Au antigenemia by the IEOP, EID, 
and CF examinations (Fig. 9) immediately 
before transplantation. The ACA was also 
elevated (Fig. 9). 
At the time of operation, she had 9 liters 
of ascites, bilateral pleural effusions and 
jaundice. Liver function tests were typical 
of terminal hepatic disease including hypo-
albuminemia «2.0 Gm./lOO ml.) and a 
depressed prothrombin time «200/0). She 
also had striking hypergammaglobulinemia 
(4 Gm./100 ml. or more). 
In spitc of her poor condition prior to the 
transplantation, the early postoperative con-
valescence was uncomplicated. Immuno-
suppressive treatment included the use of 
azathioprine, prednisone, and horse ALG 
(Fig. 9). Hepatic function was excellent 
from the beginning. The high serum con-
centration of gamma globulin promptly 
fell (Fig. 9). 
Within 30 minutes after host hepatec-
tomy, all serologic evidence of persistent 
hepatitis had disappeared by the AG, EID, 
IEOP, CF, and ACA tests. Almost 6 weeks 
later, the CF, EID, and IEOP returned to 
positive, followed almost a month later by 
the same change in the AG. 
One week after all the hepatitis detection 
tests had become positive and 80 days after 
the transplantation, the patient was re-
admitted with increases in the transaminases, 
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TABLE 6. Electronmicrographic Studies of Heated (56 0 C. for 30 minutes) Sera from 
Patients Who Had High ACA Tilers 
Anti-Au IgG* Fraction Examined Virus-like 
Patient No. Type Recipient Au Added to Sera by EM Particles Seen 
1 Kidney +All Yes Precipi ta te Yes*** 
2 Kidney +All Yes Precipitate Yes*** 
3 Liver No Purified ACA No 
4 Liver +CF** No Purified ACA Yes*** 
* By EM, this IgG did not contain virus particles. 
** The positive CF test became evident 4 days after the serum with high ACA was collected, analyzed and 
found to contain the virus-like particles seen in Figure 8. ' 
*** These virus-like particles were often surrounded by halos that were interpreted to be antibody (Fig. 8) as 
described by Almeida et al.1 
jaundice, alkaline phosphatemia, and de-
pression of the prothrombin time to 5070. 
For several days she had marked loss of 
appetite. The diagnosis of recurrent hepa-
titis was made, rather than that of delayed 
homograft rejection. Consequently, immuno-
suppression was not increased. The bio-
chemical abnormalities of the presumed 
hepatitis developed and largely receded 
over a period of 8 weeks (Fig. 9). How-
ever, the evidence of Australia antigenemia 
has persisted to the present time 8 months 
post-transplantation. 
Discussion 
It has not yet been established that the 
Australia antigen is the actual serum hepa-
titis virus.5 , 14, 47 The most fundamental 
reason for withholding judgment on this 
question is that DNA or RNA has not been 
proved to be present in the Au antigen"; 
one or the other of these nucleic acids must 
be present if it is a virus. Nevertheless, the 
evidence suggests either that the Au anti-
gen is the serum hepatitis virus or some-
thing very closely associated with it. The 
work of Krugman and Giles 36 and of Barker 
et al. 4 has shown that the Au antigen is 
infectious. Moreover, Au positive serum 
usually contains particles that look like 
viruses of the Picorna class,"' 51 approxi-
mately 200 A in diameter.l, 2, 4, 5, 20, 2R, 35, 47, 
51, 58 
Conceding for the moment that the Au 
antigen is the serum hepatitis virus, it is 
hardly surprising to find an increased inci-
dence of this agent in the transplant popu-
lation. In Blumberg's initial studies and in 
a number of subsequent ones, the Au anti-
gen was found with increased frequency in 
patients with a variety of natural immuno-
logic deficiency states including Down's 
syndrome, D, 13, 71, 72 leukemia,7, 9, 12 lep-
rosy 10, 11 and uremia. 24, 37, 39, 40, 77 In our pa-
tients, an analogous host background of 
partial immunologic invalidism was pro-
vided by iatrogenic immunosuppression. Al-
though reports of documented serum hepa-
titis under this latter circumstance have 
been few in number/G, 37, 41, 51, 62, 6G, 70 this 
is undoubtedly because technics for Au 
antigen detection have been widely em-
ployed only in the last year or so. It can be 
expected that serum hepatitis will be found 
in every large transplantation program pro-
viding the appropriate survey is conducted. 
The incidence is only the beginning of 
the total problem in assessing the signi-
ficance of serum hepatitis under conditions 
of chronic immunosuppression. Of greater 
import is the fact that a patient once in-
fected under these circumstances cannot 
recover in the traditional sense and rid him-
self of the microorganism, at least as its 
presence is measured by the precipitating 
methods (AG, EID, and IEOP). It is of 
some theoretical interest to note that sero-
logic recovery can occur if the Au antigen 
is detected only by complement fixation 
( CF). Possibilities for this divergent find-
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ing are, first, that the virus doses being 
measured by the CF method are small 
enough to be cleared by the residual host 
defenses or, second, that the CF determines 
something that is qualitatively, not just 
quantitatively, different than that measured 
by the precipita ting techniques. 
The observation "once Au positive, alteays 
Au positive," if the detection has been with 
a precipitation technic, has important con-
sequences. An infected patient becomes a 
carrier capable of infecting other organ 
recipients or the immunologically normal 
people who are providing ongoing care. For 
FIG. 8. Virus-like par-
ticles isolated from the 
anticomplementary activ-
ity (ACA) purified from 
the serum of a liver re-
cipient who was Au anti-
gen nega tive but whose 
serum had a high ACA 
titer. The isolated ACA 
was negat ively stained 
with the conventional 
ph osp ho tu n gs ti c acid 
method. The virus-like 
particles had diameters 
of 160-2,50 A. The elec-
tron micrography was 
eerformed by Paul Na-
ane, M.D. (x 500,000). 
example, both parents of the renal recipient 
whose serum serves as our Au antigen 
standard have developed serum hepatitis. 
In the last 9 years, more than a dozen of 
the professional team working in our trans-
plantation unit have developed hepatitis 
and one, a research technician, has died. 
Au tests were performed only on the last 
three afflicted staff personnel, and these 
were positive, including the fatal case. By 
personal communication, 40, 78 it is known 
that deaths of staff members from serum 
hepatitis have been observed at other trans-
plantation and dialysis centers. 
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FIC. 9. The course of 
a patient with chronic 
aggressive hepatitis, Au 
positive, who was treated 
with liver replacement. 
Immediately after trans-
plantation, all the sero-
logic evidence of hepa-
titis disappeared, only to 
return subsequently. 
Kotc the profound hyper-
gammaglobulinemia ( 4 
Gm./IOO m!. or more); 
albumin which was 2 
Gm.jIOO ml. or less pre-
operatively rose to and 
remained at normal lev-
els after placement of 
the new liver. 
AG 
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With this particular virus, the risks im-
posed by infecting hospital personnel are 
relatively predictable, as judged by the 
enormous literature concerned with the 
mortality and morbidity of serum hepatitis. 
The immunologically normal person with 
florid disease has a mortality of 1 to 
12%.50. 61 Another small per cent develop 
chronic and progressive hepatic disease. 
The vast majority recover fully. 
The implications of serum hepatitis in 
the chronically·immullosuppressed recipient 
who has continuous viremia from which he 
cannot hope to recover are by no means so 
well known in terms of liver function over 
a period of years. It has been suggested hy 
some authorities that the virulence of hepa-
titis under conditions of immunosuppression 
is considerably less than in a normal 
person, 37. 62 presumably by the coincidental 
prevention of autoimmune sequellae of 
hepatocellular injury. Such opinions have 
been used to rationalize the wisdom of im-
munosuppressive treatment of patients with 
chronic aggressive hcpatitis. Stated dif-
ferently, the proposition would predict that 
serum hepatitis would be less dangerous to 
the immunosuppressed transplant patient 
than to his nurses or physicians. 
The foregoing hypothesis cannot be re-
futcd by the observations in the present 
investigation since there was no mortality 
from proven serum hepatitis amongst the 
studied transplantation patients whereas a 
non-immunosuppressed technician died dur-
ing the same interval. Nevertheless, the 
notion that immunosuppressive agents arc 
liver-protective can hardly be strongly sup-
ported by a group of organ recipients of 
whom more than half had hepatic injury 
from whatever cause. The most that can be 
said is that serum hepatitis was not the 
major cause of the high incidence of hepa-
tic damage in this patient population since 
the biochemical indices of injury were es-
sentially the same with or without Au 
antigenemia. Because of this latter fact, 
exclusion of candidates for renal trans-
plantation because of an Au positive test 
cannot be justiRed on the basis that the re-
cipient would be thereby placed at an 
exorbitant risk. 
The same conclusion applied to the pa-
tient in the present report who was dying 
of hepatic failure secondary to chronic 
aggressive hepatitis, Au positive. In this 
case, removal of the diseased organ was 
followed within a few minutes by the com-
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plete disappearance of all serologic evi-
dence of the Au antigen from the peripheral 
blood, indicating that the primary source 
feeding the antigenemia had been the liver. 
That it was not the sole repository of the 
virus was suggested by the subsequent re-
currence of the hepatitis at about the same 
time as would have been expected with an 
initial exposure to virus at the time of 
transplantation. 
For infectious diseases, the incubation 
period is often thought of in terms of the 
host immunologic apparatus. A somewhat 
different view is necessary in our patient 
whose liver was replaced. In this case, the 
latent pcriod seemed intrinsic to the tar-
get organ, the liver. When the liver finally 
exhibited injury, the extrahepatic mani-
festations of serum hepatitis also became 
evident, including such complaints as ex-
cruciatingly painful joints. Recovery then 
followed in much the same way as after 
her first attack of acute serum hepatitis 6 
years previously. 
The long-term prognosis of this hepatic 
"ecipient remains guarded. However, there 
are two reasons to hope that her new or-
gan will not suffer the same fate as her na-
tive liver. First, as discussed earlier, im-
munosuppression may help prevent the 
ravages of progressive hepatic disease, at 
least as these are dependent upon an auto-
immune component. Second, the homo-
graft may be less susceptible to chronic 
aggressive hepatitis if the recently pro-
pounded theories of genetic predisposition 
to serum hepatitis 8,"" have validity. He-
patic homografts have been proved to re-
tain donor genetic specificity for years and 
probably pem1anently after transplanta-
tion. 3 , 33, 38, 45, 68, 70 Consequently, the trans-
plantation of the liver from a donor who 
possessed genetically determined resistance 
to hepatocellular injury could be a major 
advantage. Third, the patient has had no 
sign of the hypergammaglobulinemia that 
was such a prominent feature before 
transplantation. 
Although potential renal and hepatic re-
cipients cannot logically be denied trans-
plantation on grounds that a positive Aus-
tralia antigen tests would subject them to 
a prohibitive risk, a decision against the 
undertaking could be justified on the basis 
that the creation of a dangerous endemic 
hepatitis pool within the hospital is unwar-
ranted. After much discussion within our 
group, we have decided that chronic Au 
antigenemia should not a priori exclude 
patients for transplantation, providing the 
appropriate infectious precautions are car-
ried out including training the patient to 
be impeccable about personal hygiene. It 
seems to us that the major problem in the 
past has been the unknOWing entry of hepa-
titis carriers into the program. The single 
most important identifiable source of hepa-
titis in our transplantation patients has 
been pretransplantation renal hemodialy-
sis, accounting for almost half our cases. It 
may be assumed that at least some of the 
other half were infected by members of the 
first group in the course of sharing the 
ward facilities. 
Now that Au tests are available for 
screening, this kind of hazard can be mini-
mized since at least it will be known in 
advance which patients constitute a threat 
and require speCial isolation care. If hepa-
titis is to be kept to a minimum, othcr 
screening procedures will be essential, in-
cluding examination of blood donors. Au 
antigen tests should also be performed on 
all prospective organ donors. Recently, a 
cadaveric donor, who had been pro-
nounced dead in one of our hospitals on 
the basis of irreversible neurologic injury, 
was discovered to have high titer Au anti-
genemia. If this had not been detected 
either 3 or 4 of his organs would have been 
transplanted and in addition his corneas 
would have been placed in the eye bank. 
Although control of the serum hepatitis 
problem is predictably going to be one of 
the major tasks of any large transplanta-
tion program, there is no assurance that 
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such efforts will influence the high inci-
dence of liver disease in these patients 
since so many recipients with negative Au 
tests develop abnormal hepatic function. 
Other viruses, such as those responsible for 
infectious hepatitis (IH), could be respon-
sible. If this were so, it would have been 
expected that the anticomplementary ac-
tivity (ACA) might have been elevated in 
consequence of the formation of complexes 
of the virus antigen and antibody. In-
creases of ACA were observed by Chang 
and O'Brien during the IH epidemic of the 
Holy Cross football team.1S However, in 
our patients, ACA increases were confined 
essentially to those renal patients with the 
Au antigen or to all hepatic recipients with 
or without Australia antigenemia. This 
constituted indirect evidence that infec-
tious hepatitis was not a major factor in 
the liver injury found in our patients. 
It is conceivable that further studies of 
ACA will lead to a better understanding 
either of serum hepatitis or of the com-
plex immunologic events in the transplant 
patient. The ACA examined in the present 
study was shown to be separate from sev-
eral other recognized complement inhibi-
tors. It was demonstrated to be distinct 
from C1 esterase inhibitor 21 by virtue of 
its heat stability, to have different physical 
characteristics (Fig. 7) than C3 inactiva-
tor,74, 76 and to have no relationship to 
rheumatoid factor. 
In renal patients, the association of ACA 
with the Australia antigen could be made 
with nearly perfect reliability. If, as seems 
likely, the ACA in these patients consists 
of Au-antigen-anti-Au antibody complexes, 
these circulating complexes could contrib-
ute to the glomerulonephritis commonly 
found in the transplants 44, 69 by a mecha-
nism comparable to that described by Old-
stone and Dixon in the lymphocyte chorio-
meningitis virus experimental mode1.52 
In contrast, all the recipients of liver 
homo grafts possessed ACA, whether or not 
Au antigen was diagnosed. The purified 
ACA of one Au positive patient was shown 
to contain virus-like particles and sur-
rounding halos that looked like antigen-
antibody complexes. However, the purified 
ACA of another patient who was Au nega-
tive did not have detectable virus ultra-
structurally despite even higher titers. Con-
sequently, the ACA in liver patients may 
have a special significance over and above 
any association with the Au antigen. This 
would not be suprising in liver recipients, 
inasmuch as high ACA titers have been 
seen in several diseases that have in com-
mon abnormalities of protein metabolism, 
including hypergammaglobulinemia, cryo-
globulinemia, and multiple myelomaY' 19 
In the absence of any evidence of an 
infectious etiology for progressive hepatic 
disease in the post-transplantation period 
of a given patient, serious consideration 
must be given to the possibility of drug 
hepatotoxicity with particular reference to 
azathioprine.G7 ,70 In such cases, a change 
in therapy should be considered. As a re-
placement for azathioprine, cyclophos-
phamide has received inadequate attention 
despite its impressive advantages. It has 
little hepatotoxicity,4S is one of the best 
immunosuppressive agents in rodents,6,15. 
23, 25, 32, 42, 73 and was even shown on a lim-
ited trial basis a number of years ago to 
be capable of prcvcnting renal homograft 
rejection in humans.23, 27, 54, 55 In one of 
our patients, a change was made from 
azathioprine to cyclophosphamide in De-
cember, 1970. After many weeks the seri-
ously deranged liver function tests began 
to improve. No deterioration in renal func-
tion has occurred during the 3 months of 
cyclophosphamide therapy. 
Summary 
The hepatitis associated or Australia 
(Au) antigen has been found with precipi-
tating detection methods in the sera of 
almost one-fifth of a group of 89 chronic 
survivors after renal, hepatic, or cardiac 
transplantation. An additional two recipi-
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ents were shown to possess anti-Au anti-
body. Using a more sensitive complement 
fixation test, sevcral additional diagnoses 
of Au alltigenemia were made, so that 2870 
of the studied patients had serologic evi-
dence of having had or, more commonly, 
of having contact with the serum hepatitis 
virus. 
Once Au antigenemia developed in the 
immunosuppressed patient, it seldom dis-
appeared and these organ recipients be-
came infectious carriers. Before detection 
methods for the Au antigen were available, 
a number of Au positive patients were un-
knowingly entered into the transplantation 
program already infected from dialysis or 
blood transfusion. In turn, staff members 
treating these carriers frequently devel-
oped aeute hepatitis and in one instance 
the consequencc was the death of a re-
search technician. 
In the recipients of renal homo grafts 
who had serial hepatic function as well as 
serologic tests, there was an incidence of 
liver malfunction at some time in the post-
transplantation period exceeding 507'0. 
However, the frequency of either minor or 
major derangements in hepatic fUllction 
was essentiallv the same with or without 
Au antigcllemia, suggesting that serum 
hepatitis was not an overriding or even the 
most important factor in the production of 
the well-documented liver disease that oc-
Cllrs after renal transplantation. 
Anticomplementary activity (ACA) has 
been said to rcflect thc presence of circu-
lating antigcn-antibody complexes. In both 
the symptomatic and asymptomatic renal 
recipients with chronic Au antigenemia, 
the ACA titers were essentially always ele-
vated. Their sera contained virus-like par-
ticles. In contrast, ACA titers were almost 
ne"er almormal in the Au negative renal 
recip:ents. This finding was construed as 
evidence against the pOSSibility that liver 
disease in the A.u negative patients was 
being caused by a different kind of virus, 
such as the infectious hepatitis (IH) vari-
ety. In some instances, drug hepatotoxicity 
may have been responsible. In one case, 
azathioprine was so strongly suspected that 
it was discontinued and replaced altogether 
with cyclophosphamidc. This kind of 
change in therapy should probably be con-
sidered more frequently in such cases. 
In liver recipicnts, the increases in ACA 
were not confined to patients with Au anti-
genemia but were always present. In two 
recipients with high ACA titers, one Au 
negative and one Au positive, the ACA 
was highly purified with chromatographic 
techniques. The product from the Au posi-
tive serum contained virus-likc particles, 
whereas the ACA in the other case did not 
have this finding. 
On the basis of much of the foregOing 
information about serum hepatitis under 
conditions of chronic immunosuppression, 
a patient dyillg of chronic aggressive hepa-
titis, Au positive, was submitted to liver 
replacement and then treated with azathio-
prine, prednisone, and heterologous ALG. 
vVithin minutes after host hepatcctomy, the 
Au antigen disappeared from the serum 
suggesting that the native liver had been 
its primary source. The antigen returned 
many weeks later jllst before the onset of a 
modcrately severe bout of hepatitis affect-
ing the homograft. The patient has almost 
completely recovered from this incident 
and is now 8 months post-transplantation. 
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DISCUSSION 
DR. JOHN S. NAJARIAN (Minneapolis): I would 
like to compliment Dr. Starzl on an excellent 
study on this group of patients. I would like to 
make one comment, and ask him two questions. 
(Slide) We transplanted a patient about a 
year amI a half ago who had a snhacnte hepatitis 
with decreasing l,epatic function and who wpnt 
into hepatic-renal failme; eventually we did a 
hepatic transplant on this patient. This led to 
many problems, including yours truly, who 
developed hepatitis. I would lih, to show you 
what occnrred prior to the time of this transplant. 
Here is the hepatiC transplant; it was done at 
this point. Prior to that time the total numher of 
cases of hepatitis among hospital and laboratory 
personnel, transplant personnel, dialysis personnel, 
was about this rate; and yet we had several pa-
tients with positive Australia antigens, and at lcast 
in most instances, subicteric hepatitis. 
The transplant was performed at this point, and 
you can sec the tremendous number of cascs that 
resulted-a total of 46. It was pointed out to me 
by Dr. Simmons, who made this slidc, that I am 
one of these Iittlc black squares. 
The total cases is shown here, over periods ex-
tending from approximately two and one-half 
months from the time of transplant on, most of 
which could be directly related to this transplant 
in this paticnt with hepatitis. 
Who was affected? It was the hospital per-
sonnel, the transplant personnel; interestingly 
enough, the dialysis personnel were much more 
careful than the rest of us, and didn't have au 
increased incidence of hepatitis. There was no 
increase of hepatitis in the dialysis patients. There 
was only one case in a posttransplant patient. The 
number of transplants that we were doing on a 
monthly basis was about at the same rate as it 
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vVoodruff, M. F. A., Edinhurgh. Personal Com-
munieation. 
was before this time, so we did not dccrease our 
activities. 
I simply bring this out to corroborate what 
Tom said; and that is that the ones not at risk arc 
the dialysis patients and the transplant patients-
the dialysis patients perhaps because they are im-
munosuppressed from their uremia, and the trans-
plant patients, perhaps because they were immuno-
suppressed as well. All of us nonimmunosllppressed 
patients fit in this category (active hepatitis). 
I would like to ask Tom two questions. The 
first relates to the claim (sic) that he has trans-
planted one patient with hepatitis. I am \\"Olldpring 
if the data that is accumulating now will indicate 
that, perhaps, we should consider the possibility 
of immullosllppressing a patient who contracts 
lwpatitis, lJad as that sounds? We bave toyed 
with this for some time because immunosuppressed 
patients do so well. Perhaps the major destruction 
to the liver occurs hecanse of thc host response to 
the virus in the ]h'er. If immnnosuppression is 
used, it may be a method of handling paticnts 
with hepatitis-specifically, the older patients in 
whom the mortality, as you know, goes up rather 
precipitously. 
The second question has to do with an ob-
servation that he mayor may not have made on 
some of these patients. It has been recently re-
ported in The Lancet that a group of patients that 
had hepatitis on dialysis showed an increase in 
erythropoitin. Thcse authors discovercd this cIFect 
by accident, as you know, v"hen they saw that the 
rcqnirement for transfusion in some patients was 
diminishing and they correlated this finding with 
patients who developed hepatitis on dialysis. They 
made the suggestion that under these circum-
stances the liver is not degrading erythropoitin jf 
this occurs and there were increased erythropoitin 
\evels, increased hcmoglobin, and a decreased need 
{or transfusion. 
Ann. Surg .. Oct. 1971 
Vol. 174 No.4 
HEPATIC DISEASE IN HOMOGRAFT RECIPIENTS 638 
I wonder if this was seen in any of the patients 
that Dr. Starzl described with positive Australia 
antigen, or hepatitis. 
DR. J. GARROTT ALLEN (Palo Alto): This has 
been a fascinating presentation, and on a subject 
that I have been interested in for many years. One 
of the most difficult things to explain in transfusion 
hepatitis is the existence of the carrier donor. How 
does such an individual manage to harbor the in-
fectious agent of hepatitis (presumably a virus) 
for so many years without himself developing 
evidence of liver disease? The carrier and his 
virus seem to adapt themselves very well to each 
other. 
One cannot escape the concept of tolerance in 
such a state-tolerance of the carrier for the 
virus and tolerance of the virus for the carrier. If 
we understood this mechanism, the rejection prob-
lem of transplantation would also be solved. 
The possibility of a carrier state and its rela-
tionship to impaired host immunity in hepatitis 
first occurred to me in 1947, when in the course 
of treatment of the first patient with hypo- or 
agammaglobulinemia, we discovered that this pa-
tient did not develop hepatitis despite our supply-
ing her with gammaglobulin in pooled plasma and 
blood for the next 12 years. A similar observation 
has more recently been reported by a number of 
workers who have noted that posttransfnsion hepa-
titis acquired in patients on immunosuppressive 
therapy usually runs a very mild course. In the 
dialysis units and on transplantation services few 
if any of these patients have died of hepatitis, 
but this is not true of the staff taking care of these 
patients. As Dr. Najarian and others have noted, 
the fatalities have tended to occur among the 
personnel, people not on immunosuppressive 
agents. "Vitll a normal immnne response, they 
slowly produce antibodies, and eventually four to 
eight weeks later, there is a "confrontation" of the 
virus with the antibodies in the hepatic cells that 
leads to cellular destruction. 
In this discussion, one is reminded of the 
significance and eloquence of von Pirquet and 
Schick's book, "Serum Sickness," first published 
in 1905, and translated from German into English 
by Schick in 19.51. The point of their study that 
is relevant to this discussion can be paraphrased 
as follows: No antibody formation-no disease. 
The same concept probably applies to many 
organisms that are nonpathogenic for man, simply 
because they do not provoke an antibody response. 
This, in a sense, is what we are approaching, it 
seems to me, in patients with posttransfusion hepa-
titis on immunosuppressive therapy, an antigen in 
man unable to produce antibodies. In many in 
stances there is no point in keeping these patients 
in the hospital for their hepatitis, though regula-
tion of their immunosuppressive therapy requires 
it. These patients should be considered highly 
infectious to hospital personnel and visitors. 
Dr. Najarian mentioned the possibility of 
treatment of hepatitis with immunosuppressive 
agents. We have wondered about this too, but 
usually by the time the patient has hepatitis, his 
disease is far enough advanced that immunosup-
pressive therapy may carry a much greater hazard 
than when the disease develops in a patient al-
ready on immunosuppressive therapy. As far as I 
know, we have had no deaths from hepatitis 
among patients on immunosuppressive therapy. 
I would like to raise a point with Dr. Starzl: 
The best results for the detection of the Au anti-
body that I know of, are those from Dr. Prince of 
the New York Blood Center. As of last week, I 
had a letter from him to the effect that by what-
ever test his laboratory has attempted to use, a 
maximum of only twenty-five per cent of infectious 
donors was detected. Similar reports have come 
from the NIH and others. It makes one begin to 
question if three fourth of the cases are not due 
to some other agent than the Au antigen. Al-
though Au screening is recommended, it seems 
rather a futile method of reducing the incidence 
of the disease at this time. 
And this is a serious consideration, it seems to 
me, when one realizes that the average patient, 
leaving out the heart cases, gets about four units 
of exposure. To take one of those four possibilities 
ont, I don't believe is going to do anything to our 
present attack rate. 
DR. ALAN G. BmcH (Boston): We have had 
the unfortunate task of reviewing the long-term 
data on 37 cases of clinical hepatitis which occurred 
on our dialysis and transplant unit during a 
16 month span in 1969 and 1970. There were 14 
cases occurring in dialysis patients, out of a pool of 
approximately 150 patients at risk, 13 cases among 
the 70 transplanted patients during this time, and 
ten cases out of about 80 staff exposed. 
Our experience substantiates the impression 
and points made by both Dr. Starzl and Dr. 
Najarian and others, that there certainly is a 
gradation in the clinical severity in these cases. 
The dialysis and transplant patients have mild 
cases. They do, however, usually show significant 
enzyme rises, whereas the cases in the staff have 
been far more severe clinically, and one dialysis 
nurse and one patient's wife have succumbed from 
hepatic failure. 
Our experience does not substantiate the con-
tention made by Dr. Starzl that persistent Austral-
ian antigencmia is inevitable in the immunosup-
pressed patient. It has been our policy to decrease 
or discontinue Imuran when hepatitis is clinically 
diagnosed, and we have discontinued Imuran for 
20 to 380 days, for an average of 160 days, in 12 
such patients. 
The Australian antigen, measured by the some-
what crude immunodiffusion technic, has remained 
negative in five of these patients, including one 
who had a positive antibody titer. Three of four 
patients who started with a positive Australian 
antigen when Imuran was discontinued, have con-
verted to negative during the subsequent 3 to 6 
months. Two patients in whom Imuran was not 
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discontinued were, and have continued to be, 
Australian antigen positive. 
While the patient is off Imuran, we have not 
added additional immunosuppressive drugs, but 
have merely slightly increased the prednisone dose. 
Yet only three episodes of rejection have occurred 
in a total of 1700 days at risk off Imuran. This very 
low rejection rate makes us wonder if there is 
indeed some protective effect engendered by the 
deranged hepatic function, or possibly due to the 
rise in anticomplementary activity described by 
Dr. Starzl. 
Finally, we would like to say that the con-
tention by Dr. Starzl that decreasing the Imuran 
indeed may be good for the liver itself-is sug-
gested, in that six of the 12 patients in whom 
Imuran was discontinued, three with and three 
with negative Australian antigen, have had re-
current enzyme rises when Imuran was reinsl i-
tuted. These rises have quickly fallen back to 
normal when Imuran was again discontinued, and 
have, in five of the six cases, allowed Imuran to be 
started again only after some months of further 
followup. 
DR. THOMAS E. STARZL (Closing): 
Dr. Najarian, I can't help but note that those 
most eoncemcd with epidemiologic studies of 
hepatitis, have an interest that correlates with their 
own previous serum bilirubins. 
Dr. Najarian raised two questions. The first was 
whether or not immunosuppression should be used 
for patients who become ill with serum hepatitis. 
This question was asked of me by Dr. Francis 
Moore in Los Angeles recently, and I will now give 
the same answer as I gave him, but perhaps with 
somewhat less assurance. The answer was no. 
It may be, as Dr. Najarian has suggested, that 
the chance of dying from acute hepatitis under 
conditions of immunosnppression is less than in 
the normal patient. However, the penalty of im-
munosuppression appears to be chronic Australia 
antigenemia. I sllspect that in the long run some-
body with chronic Australia antigenemia will be 
subject to a whole variety of risks, of which some 
are not even yet known. Chronic aggressive hepa-
titis would be one possibility, and this would be 
unacceptable in a disease that has 90% total re-
covery rate, as you yourself experienced, Dr. 
\:ajarian. 
Moreover, there are other chronic hepatic 
diseases in the etiology of which Australia anti-
genemia has been implicated or speculated about. 
These include primary biliary cirrhosis and even 
hepatoma. These are some of the reasons my 
ans,-,'er is no. 
I'm sorry to say that I have no information on 
the second question which concemed erythropoitin. 
As to Dr. Prince's observations, I think that 
Dr. Prince believes that his IEOP method is 
nearly 100% ac.curate if the diagnosis is serum 
hepatitis and if samples can be obtained at the 
appropriate stage of the disease. Of course, there 
are other kinds of hepatitis than that detectable 
by the Au testing, which is the point made by Dr. 
Allen. Consequently, the mere use of Au screening 
will not eliminate hepatitis, although certainly the 
testing is worthwhile. 
Dr. Allen, it seems to me, has raised the really 
key issue about the rcason for chronic Australia 
antigenemia in immunosuppressed patients. The 
tolerance theory mentioned by Dr. Allen was 
described a number of years ago by Professor 
Burnctt of Australia as an explanation of chronic 
viremia. With immunosuppression, the conditions 
are propitious for the development of tolerance, 
including as they do the continuous presence of 
the antigen, plus immunologic weakening. In turn, 
this combination of circumstances is precisely that 
which Dr. Robert Schwartz, of Boston, thought 
important for tolerance induction in his first re-
ports about Imuran in 1959. In this classic paper 
he showed that tolerance to bovine serum albumin 
(BSA) could be produced by administering BSA 
and Imuran together. It is not hard to similarly 
envision the hapatitis virus plus immunosuppres-
sion leading to tolerance to the virus at the same 
time as renal antigens plus the same immunosup-
pression lead to kidney graft acceptance. 
Concerning the whole question of tolerance, I 
didn't want to leave that subject without compli-
menting Dr. Pierce and Dr. Marehioro for what I 
think may well be a hallmark paper given at this 
meeting. They have shown us how we can get at 
some of the mechanisms of graft acceptance in a 
way that is different and easier than in those 
pioneer studies presented by Dr. Joe Murray to 
this association in his paper of 1964 on canine 
renal transplantation. With the technics of Pierce 
and Marchioro, the essential inquiries can be made 
in a test tube, or on a plate, rather than requiring 
complicated experimental protocols such as those 
previously used. 
Finally, I think there's nothing essentially in-
consistent about the observations at Denver and 
at the Peter Bent Brigham Hospital. I think if one 
really wanted to get rid of chronic Australia anti-
genemia, the only reasonable way to do it would be 
to stop immunosuppression. It just happens that 
we have not done that, and the group at the 
Brigham have. Since they have, they have coinci-
dentally performed a tolerance experiment in those 
dozen or so patients who have had their immuno-
suppression stopped. It is heartening to see in the 
human that the rate of continuing graft function 
after discontinuation has been higher than that in 
the experimental animal, or more specifically the 
dog. 
